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Abstract 
Osimertinib is the standard therapy for epidermal-growth-factor-receptor 
(EGFR)-mutant lung cancers. Herein, we report a case of osimertinib-induced 
interstitial lung disease (OsiILD) with organizing pneumonia (OP) pattern and 
provide a literature-based review. Six months after osimertinib administration, a 
75-year-old woman with right pleural carcinomatosis developed ILD with OP 
pattern. After salvage chemotherapy, osimertinib with corticosteroid was 
successfully re-administered. Literature review suggested that 1) OsiILD with 
OP pattern was rare but should be recognized, 2) re-administration of 
osimertinib in OsiILD was successful in selected patients. A criterion that 
determines whether a patient would benefit from re-administration is warranted. 
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Introduction 
The discovery of driver mutations has drastically changed clinical practice in 
patients with lung tumors. The management of lung cancer with appropriate 
oncoprotein inhibitors is vital for patient survival (1). Osimertinib is a 
third-generation irreversible epidermal-growth-factor-receptor (EGFR)-tyrosine 
kinase inhibitor (TKI) that has positively changed the standard treatment for 
non-small-cell lung cancer harboring EGFR T790M mutation (2-4). Therefore, 
continued treatment with osimertinib is crucial for patients with EGFR-mutant 
lung cancer. 
Unfortunately, some patients discontinue the use of EGFR-TKIs due to 
toxicities. Drug-induced interstitial lung disease (ILD) is the most common 
serious adverse event that occurs during EGFR-TKI treatment. Previous clinical 
trials have reported that osimertinib-induced ILD (OsiILD) occurred in 2–4 % of 
patients (2-4). However, only few case reports describing OsiILD have been 
published, and the specific clinical features are not fully understood. Notably, 
some cases reported successful re-challenge of patients with osimertinib, even 
after suffering from OsiILD. Herein, we report the case of a patient having 
OsiILD with OP pattern, re-challenged with osimertinib and provide a 
literature-based review. 
 
Case 
A 75-year-old woman with no history of smoking or allergies had a 
postoperative recurrence of lung adenocarcinoma harboring the EGFR exon 19 
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deletion. She developed cancer-related pleural effusion, which disseminated to 
the right lung. The patient’s Eastern Cooperative Group Performance Status 
(PS) was grade 1; thus erlotinib was administered. Three months after initiation 
of erlotinib, pleural dissemination and effusion were reduced. (Fig 1A, B). 
However, pleural dissemination and effusion increased 1 year after beginning 
the erlotinib treatment. Genetic testing of the pleural fluid revealed EGFR exon 
19 deletion and EGFR T790M mutation in cancer cells. The patient’s PS 
maintained at grade 1. Thus, osimertinib was provided, and pleural 
dissemination to the right lung almost disappeared 3 months after the initiation 
(Fig.1C, D); however, the patient complained of cough 6 months after starting 
osimertinib administration. A chest high-resolution computed tomography 
(HRCT) scan revealed patchy consolidation with a reversed halo sign in the left 
lower lung lobe (Fig.2A, B). We suspected that the ILD with an OP pattern was 
induced by osimertinib; therefore, the anti-cancer drug was immediately 
discontinued, and she was admitted to our hospital for diagnosis and treatment. 
At that time, her oxygen saturation was 98 % in room air. Therefore, we thought 
the lung injury was mild based on “Consensus statement for the diagnosis and 
treatment of drug-induced lung injuries” edited by the Japanese respiratory lung 
society (5). 
A bronchoscopy was performed on day 2 following hospitalization. We 
performed a transbronchial lung biopsy from the right posterior segment (S2). 
The pathological examination did not detect specific findings, including the 
existence of malignant cells or granuloma. The cellular composition of the 
bronchoalveolar lavage (BAL) fluid was the following: lymphocytes, 58.5 %; 
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eosinophils, 0.5 %; neutrophils, 0 %; monocytes, 3.0 %, and macrophages, 
38.0 %. The CD4/CD8 ratio was 0.20. Cytology and polymerase chain reaction 
test for Pneumocystis jirovecii of the BAL fluid was negative. The screening of 
general bacterial culture and acid-fast Bacillus smear and culture were all 
negative. Blood tests to rule out infections were performed, and the results were 
follows; procalcitonin ＜0.05 ng/mL; (1,3)-beta-D-glucan ＜6.0 pg/mL; 
cryptococcal antigenemia: negative; Interferon-gamma release assay 
(T-SPOT.TB ®): negative, cytomegalovirus viral antigen (pp65.C7-HRP): 
negative, and anti-mycoplasma pneumoniae IgM antibody: negative. The 
concentrations of serum Krebs von den Lungen-6 and surfactant protein-D were 
1011 U/mL (reference range, 0-500 U/mL) and 77.3 ng/mL (reference range, 
0-110 U/mL), respectively. Therefore, the patient was diagnosed with OsiILD. As 
expected, the consolidation shadows gradually improved with 0.6 mg/kg 
prednisolone (30 mg) (Fig. 2C). Prednisolone was tapered as follows: 30 mg 
daily for 1 week, 20 mg daily for 1 week, 15 mg daily for 4 weeks, 10 mg daily for 
2 weeks. After that, 5 mg of prednisolone was continued. Fortunately, ILD did 
not recur during the tapering. After tapering the prednisolone dose, the patient 
was treated with cytotoxic chemotherapy consisting of carboplatin, paclitaxel, 
and bevacizumab; however, her treatment was discontinued due to the onset of 
grade 3 peripheral neuropathy. Additionally, the right plural effusion gradually 
increased again during the drug holiday (Fig.2D). Her Eastern Cooperative 
Group PS was grade 1. The patient and her family had strong will to continue the 
treatment and provided informed consent to re-administer osimertinib with a 
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maintenance dose of 5 mg prednisolone daily. As a result, the patient has been 
successfully treated with osimertinib without recurrence of ILD for 7 months 
(Fig.2E). 
 
Discussion 
Herein, we reported a case of a patient with OsiILD with OP pattern who was 
successfully re-administered with osimertinib. Table 1 shows previous case 
reports of OsiILD (6-13). Our literature-based review suggested that 
ground-glass opacity was the most common HRCT finding, but some cases 
evidenced OP pattern. Our case presented patchy consolidation with a reversed 
halo sign, indicating an OP pattern. The frequency of OP pattern in OsiILD is 
unclear. Currently, few cases of osimerinib-induced ILD with OP pattern have 
been reported, although it was reported as a characteristic pattern of first 
generation TKIs-induced ILD (14-16) (Table 2). 
 Interestingly, the re-administration of osimertinib was successful in 83 % of 
the cases (5 in 6 cases) in the literature-based review. In general, ILD induced 
by EGFR-TKIs such as gefitinib or erlotinib is severe, and approximately 
one-third of these cases are fatal (17, 18). Similarly, fatal cases have been 
reported in clinical trials for osimertinib (4). To date, there is no consensus 
regarding the safety and efficacy of re-administering EGFR-TKIs in patients with 
EGFR-TKI-induced ILD. However, even though the literature shows a high 
success rate with re-administration of osimertinib, we must be cautious. The 
high success rate may be due to positive publication bias. In contrast, 
considering that osimertinib has different biological features such as 
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considerably lesser activity against wild-type EGFR than other EGFR-TKIs (19), 
disease severity, mortality, and biology of OsiILD might be different from those of 
EGFR-TKI-induced ILDs. Recently, several groups reported that osimertinib 
could induce transient asymptomatic pulmonary opacities (TAPOs) in 20-35 % of 
the patients (20-22). The radiological patterns of TAPOs included ground-glass 
opacity, peribronchial and subpleural nodules, and cryptogenic organizing 
pneumonia and/or simple eosinophilic pneumonia. According to the reports, 
these patients with TAPOs could be treated with continuous osimertinib therapy 
or a transient drug holiday followed by osimertinib re-administration (20-22). One 
explanation for the high success rates of osimertinib re-administration in our 
review might be that some patients may have developed TAPOs and not OsiILD. 
Thus far, there are no definitive ways to confirm whether pulmonary opacities 
are drug-induced ILD or TAPOs. Further assessments of the radiological 
patterns and BAL data are required to investigate this clinical issue. 
In conclusion, re-administration of osimertinib for OsiILD might be feasible in 
selected cases. Further studies are required to identify the clinical features or 
specific biomarkers of OsiILD to select which ILD patterns or patients can be 
treated or safely re-administered with osimertinib. 
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Figure legend 
Figure 1. The effect of epidermal growth factor receptor–tyrosine kinase inhibitor 
(EGFR-TKI). Black arrow indicates plural dissemination. (A, B) Chest 
high-resolution computed tomography (HRCT) image 3 months after the 
initiation of erlotinib treatment. Right pleural dissemination and effusion were 
reduced. (C, D) Chest HRCT images 3 months after the initiation of osimertinib 
treatment. Right pleural dissemination and effusion were once again reduced.  
 
Figure 2. The clinical course of osimertinib-induced interstitial lung disease with 
an organizing pneumonia (OP) pattern. (A) Chest HRCT image 3 months after 
the initiation of osimertinib treatment. No evidence of lung tumor was detected in 
the lungs. (B) Chest HRCT image 6 months after starting osimertinib treatment, 
showing patchy consolidation (arrow). Some of the consolidation accompanied a 
reversed halo sign (arrow head). Red arrow indicates lung lesion on which lung 
biopsy was performed. Lung cancer cells were not detected. (C) Chest HRCT 
image after 46 days of corticosteroid treatment, showing improvement in the 
abnormal shadow. (D) Chest HRCT image after cytotoxic chemotherapy, 
indicating an increased right plural effusion. (E) Chest HRCT image after 4 
months of osimertinib re-administration, presenting decreased right pleural 
effusion without recurrence of ILD. 
